Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue | $6,560 | — |
| Total revenue | 6,560 | — |
| Operating expenses | ||
| Research and development | 95,726 | 70,886 |
| General and administrative | 19,378 | 13,503 |
| Total operating expenses | 115,104 | 84,389 |
| Loss from operations | (108,544) | (84,389) |
| Other income |
Item 1. Financial Statements (UNAUDITED).
FAQ
- What is IDEAYA Biosciences, Inc.'s R&D?
- IDEAYA Biosciences, Inc. (IDYA) reported R&D of $95.73M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s R&D changed year-over-year?
- IDEAYA Biosciences, Inc.'s R&D increased by 35.0% year-over-year, from $70.89M to $95.73M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s R&D?
- Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s R&D has grown at a 52.5% compound annual growth rate (CAGR), from $58.16M to $314.7M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about IDEAYA Biosciences, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude